NASDAQ · CLYM
Climb Bio, Inc.
$10.16-$0.18 (-1.69%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.6% below the high.
Loading market information…
NASDAQ · YMAB · USD
Stock price, earnings
Quote as of Sep 16, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Y-mAbs Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Y-mAbs Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Y-mAbs Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and selling innovative antibody-derived therapies specifically designed to combat cancer within the United States. Its flagship product, DANYELZA, is a monoclonal antibody administered alongside granulocyte-macrophage colony-stimulating factor, targeting high-risk neuroblastoma in children when the disease has returned or proven resistant to prior treatments. Beyond its approved indication, DANYELZA is undergoing Phase II trials for new applications, including initial and third-line neuroblastoma, as well as relapsed osteosarcoma. Furthermore, Y-mAbs is progressing with a GD2-GD3 vaccine, currently in Phase II for aggressive Stage 4 neuroblastoma. Another key asset, Omburtamab, a murine monoclonal antibody, is being evaluated in clinical studies for a range of challenging conditions: central nervous system and leptomeningeal spread of neuroblastoma, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other cancers expressing the B7-H3 protein. The company's pipeline also features Nivatrotamab, which is being investigated for small cell lung cancer and is in Phase I/II trials for persistent GD2-positive solid tumors in both adult and pediatric populations. Completing its early-stage portfolio is Lu-omburtamab-DTPA, a Phase I candidate aimed at treating medulloblastoma and B7-H3 positive leptomeningeal metastases originating from solid tumors. Y-mAbs maintains a licensing arrangement with both the Memorial Sloan Kettering Cancer Center and the Massachusetts Institute of Technology, enabling it to advance and market certain agreed-upon therapies. Established in 2015, Y-mAbs Therapeutics, Inc. operates from its headquarters in New York City.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:34 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $19.93M-10.3% vs estimate |
| Q4 2023 | Feb 29, 2024 | -$0.02+90.0% vs estimate | $23.36M+0.44% vs estimate |
|---|
| Q3 2023 | Nov 13, 2023 | -$0.18+5.26% vs estimate | $20.45M-2.27% vs estimate |
|---|
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.16-$0.18 (-1.69%)
Climb Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 44.6% below the high.
$6.47$0.00 (0.0%)
Sinovac Biotech Ltd.: Healthcare · Medical - Pharmaceuticals.
$10.15+$0.02 (+0.2%)
iTeos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.43% below the high.
$8.44-$2.01 (-19.23%)
Big Cypress Acquisition Corp.’s quoted price sits in the lower half of its reported 52-week range, 34.57% below the high.
$2.10-$0.10 (-4.55%)
SomaLogic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.59% below the high.
$3.65$0.00 (0.0%)
Revance Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.72% below the high.
$16.70+$0.05 (+0.3%)
Orchard Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 0.12% below the high.
$7.16+$0.01 (+0.14%)
G1 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.42% below the high.
